Skip to main content
SpringerLink
Log in

UK's NICE draft guidance recommends midostaurin for advanced systemic mastocytosis

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • National Institute for Health and Care Excellence (NICE). NICE recommends first treatment for rare blood disorder. Internet Document : 24 Aug 2021. Available from: URL: https://www.nice.org.uk/News/Article/nice-recommends-first-treatment-for-rare-blood-disorder

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

UK's NICE draft guidance recommends midostaurin for advanced systemic mastocytosis. PharmacoEcon Outcomes News 886, 38 (2021). https://doi.org/10.1007/s40274-021-08016-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08016-3

Search

Navigation